Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Am J Ophthalmol. 2015 Dec 15;163:1–10. doi: 10.1016/j.ajo.2015.12.005

Table.

Indications for treatment of retinopathy of prematurity for clinical diagnosis milder than Type 1 retinopathy of prematurity

Subject: Eye Center (coded) Gestational age at birth (weeks) Birth weight (grams) Gestational age at time of treatment (weeks) Clinical diagnosis “Reference standard” diagnosis (when available) Indication(s) for treatment
1: OS A 25 600 42 Zone II, Stage 2, Pre-plus (mild ROP) Zone II, Stage 2, No plus (mild ROP)
  • Active ROP with fellow eye being treated for Type 1 ROP

2: OS A 25 740 39 Zone II, Stage 2, No plus (mild ROP) Zone II, Stage 2, Pre-plus (mild ROP)
  • Active ROP with fellow eye being treated for Type 1 ROP

3: OD B 27 990 47 Zone II, Stage 3, No Plus (Type 2 ROP) Zone II, Stage 3, Pre plus (Type 2 ROP)
  • Concerning structural changes (tangential traction with temporal vessel straightening)

3: OS B 27 990 47 Zone II, Stage 3, No Plus (Type 2 ROP) Zone II, Stage 3, Pre-plus (Type 2 ROP)
  • Concerning structural changes (tangential traction with temporal vessel straightening)

4: OD C 23 534 38 Zone II, Stage 3, No Plus (Type 2 ROP) N/A
  • Concerning structural changes (tangential traction with temporal vessel straightening)

4: OS C 23 534 38 Zone II, Stage 3, No Plus (Type 2 ROP) N/A
  • Concerning structural changes (tangential traction with temporal vessel straightening)

5: OD B 23 510 40 Zone II, Stage 3, Pre-plus (Type 2 ROP) N/A
  • Concerning structural changes (tangential traction with temporal vessel straightening)

  • Vitreous hemorrhage

5: OS B 23 510 40 Zone II, Stage 3, Pre-plus (Type 2 ROP) N/A
  • Concerning structural changes (tangential traction with temporal vessel straightening)

  • Vitreous hemorrhage

6: OS D 26 950 42 Zone II, Stage 3, No Plus (Type 2 ROP) Zone II, Stage 3, No plus (Type 2 ROP)
  • Concerning structural changes (thick stage 3 membrane with anteroposterior traction and concern for progression to stage 4)

  • Vitreous hemorrhage

7: OD B 25 840 41 Zone II, Stage 3, No Plus (Type 2 ROP) Zone II, Stage 3, Pre-Plus (Type 2 ROP)
  • Concerning structural changes (thick stage 3 membrane with anteroposterior traction and concern for progression to stage 4)

  • Concerning structural changes (tangential traction with temporal vessel straightening)

  • Persistent active ROP at an advanced postmenstrual age (42 weeks)

7: OS B 25 840 41 Zone II, Stage 3, No Plus (Type 2 ROP) Zone II, Stage 3, Pre-Plus (Type 2 ROP)
  • Concerning structural changes (thick stage 3 membrane with anteroposterior traction and concern for progression to stage 4)

  • Concerning structural changes (tangential traction with temporal vessel straightening)

  • Persistent active ROP at an advanced postmenstrual age (42 weeks)

8: OD C 26 1090 43 Zone III, Stage 3, No Plus (mild ROP) N/A
  • Persistent active ROP at an advanced postmenstrual age

9: OS B 28 1077 N/A (12 months of age) Zone III, Stage 1, No plus; peripheral ischemia on fluorescein angiography (mild ROP) Zone II, Stage 2, No Plus (mild ROP)
  • Persistent retinal ischemia at old age (12 months) with treatment requiring disease in the other eye

A prospectively collected database of all neonates screened for retinopathy of prematurity (ROP) from 6 major ROP centers in the United States was retrospectively reviewed to identify cases of treatment with laser or anti-vascular endothelial growth factor agents for ROP milder than Type 1 ROP. The charts of these patients were reviewed to determine the clinical diagnosis and indication for treatment. Table 1 describes each subject and eye treated for ROP milder than Type 1, the center where the patient was diagnosed (coded), gestational age and birth weight, clinical diagnosis and indication for treatment, as well as the “reference standard” diagnosis determined based on review of fundus photographs, when available. Abbreviations: OD: right eye, OS: left eye; ROP: retinopathy of prematurity. Center names have been de-identified and coded A–D